Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer

Radboud University Medical Center3,554 enrolled

Overview

Data on disease recurrence was collected for all primary colon cancer patients diagnosed in the Netherlands over the first six months of 2015. Three-year cumulative incidence, risk factors, treatment and three-year OS of locoregionally recurrent colon cancer were determined.

Study Type

OBSERVATIONAL

Enrollment

3,554

Conditions

Colonic Neoplasms Neoplasm Recurrence, Local

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed stage I-III primary colon carcinoma; * Diagnosed between January 1st and June 30th of 2015; * Surgical resection of primary colon carcinoma. Exclusion Criteria: * Appendiceal localization; * Neuroendocrine tumor morphology;

Outcomes

Primary Outcomes

Cumulative incidence of patients with locoregionally recurrent colon cancer in curatively treated primary colon cancer patients

UNIT OF MEASUREMENT: Cumulative incidence of patients with locoregionally recurrent colon cancer in curatively treated primary colon cancer patients; MEASUREMENT TOOL: Registration of diagnosis of locoregionally recurrent colon cancer in the electronic patient file. The competing-risk cumulative incidence will be calculated, which will inform on the proportion of patients who have developed locoregionally recurrent colon cancer at that time point.

Time frame: Three years

Risk factors for development of locoregionally recurrent colon cancer in primary colon cancer patients

UNIT OF MEASUREMENT: Risk factors for development of locoregionally recurrent colon cancer in primary colon cancer patients; MEASUREMENT TOOL: Registration of clinical and pathological covariates of primary colon cancer in the electronic patient file and national pathological database (PALGA). Clinical and pathological risk factors for the development of locoregionally recurrent colon cancer will be identified using multivariable competing-risk risk regression analyses, according to the cause-specific hazard approach. This will inform on specific clinical and pathological covariates which increase or decrease the risk for development of locoregionally recurrent colon cancer.

Time frame: Three years

Proportions of treatment given to patients with locoregionally recurrent colon cancer

UNIT OF MEASUREMENT: Proportions of treatment given to patients with locoregionally recurrent colon cancer; MEASUREMENT TOOL: Registration of treatment for locoregionally recurrent colon cancer in the electronic patient file. Using descriptive statistics, treatment patterns of patients with locoregionally recurrent colon cancer will be identified. Groups that will be created, will also be used to assess overall survival.

Time frame: Three years

Overall survival of patients with locoregionally recurrent colon cancer;

UNIT OF MEASUREMENT: Overall survival of patients with locoregionally recurrent colon cancer; MEASUREMENT TOOL: Registration of vital status in the national personal records database. Overall survival will be estimated for patients with locoregionally recurrent colon cancer, stratifying for different groups (i.e. treatment, diagnosis of synchronous metastases, diagnosis within first year after primary resection, etc.)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.